

***“What are the most important priorities for skin surgery and skin cancer research and why?”***

BSDS Medical Student Essay Prize- January 2023

Mohammed J Ali

Hull York Medical School

## **Table of contents:**

1. **Key...** Page 3
2. **Introduction...** Page 4
3. **Delays in skin cancer diagnosis...** Page 4-6
  - a. **What are the consequences of delays?...** Page 4-5
  - b. **Economic effects...** Page 5
  - c. **How can we avoid delays...** Page 5-6
    - i. **Mass-media campaigns...** Page 6
    - ii. **Increasing the supply of doctors...** Page 6
4. **Meeting the psychosocial needs of patients...** Page 7-8
  - a. **How can these needs be met?...** Page 7-8
    - i. **Minimising the aesthetic consequences of surgeries...**  
Page 7
    - ii. **What are some methods that can be used to improve the mental health outcomes...** Page 8
5. **Conclusion...** Page-8
6. **Bibliography...** Page 9-12

Key:

<b>ABBREVIATION</b>	<b>MEANING</b>
<b>DS</b>	Dermatological surgery/surgeon(s)
<b>SC</b>	Skin cancer
<b>MH</b>	Mental health
<b>PPE</b>	Personal protective equipment
<b>RCP</b>	Royal College of Physicians

## Introduction:

DS is an inherently challenging vocation dealing with a variety of complex conditions which have several treatments and therapies <sup>1</sup>. This results in constantly changing priorities which are determined by factors such as the needs of patients, resources, contextual reasons (e.g., COVID-19 <sup>4,5</sup>), etc. This essay will cover what I believe are the most important priorities for DS and SC such as determining the causes and effects of delays on SC care, how we can meet the psychosocial needs of patients, and what are some interventions that can be used to improve MH outcomes.

## Delays in skin cancer diagnosis:

<b><u>Cause of delay</u></b>	<b><u>Notes</u></b>
<b>Anxiety</b>	<sup>8</sup>
<b>Belief that lesion does not require surgical removal</b>	Patients commonly ignore lesions (especially when they've had previous skin cancers), until there is a notable change (e.g., colour, shape change) <sup>8,10</sup>
<b>Common misconceptions of cause</b>	E.g., some believe that only certain races (e.g. caucasians) get skin cancer <sup>8</sup>
<b>Belief that lesion was not dangerous (denial)</b>	<sup>8,10,31</sup>
<b>Lack of partner</b>	A partner could visually identify lesions, encourage seeking medical attention, as well as a source of general social support <sup>7</sup>
<b>COVID-19 pandemic</b>	Minimisation of elective procedures, lack of referrals, lack of PPE, etc. <sup>4,5,32</sup>
<b>Doctor error</b>	Misdiagnoses, unnecessary referrals (benign lesions, e.g., seborrheic keratoses), waiting for lesion changes, etc. <sup>10,34</sup>

Table.1: Some causes of delays in seeking or receiving SC treatment.

## What are the consequences of delays?

Diagnostic delays have been observed with worse outcomes for melanomas including increased mortality, due to an increased propensity for growth, differentiation and metastasis <sup>7,10</sup>. This is vital in terms of DS: e.g. earlier melanoma stages can be treated solely

via surgery<sup>9</sup> and have better outcomes (5-year survival = ~80-100%)<sup>33</sup>; however, later stages ( $\geq$ stage III) usually require adjuvant treatments like immunotherapy<sup>9</sup> and are associated with worse outcomes (5-year survival = ~30-70%)<sup>33</sup>. However, the effects from non-melanoma SCs were not as obvious, there was an associated increase in tumour size but not an observable difference in survival rates<sup>10</sup>.

### Economic effects:

Late diagnoses have an economic burden, this is attributed to the different aspects of SC care<sup>11, Table.2</sup>.

<i>Cause of cost</i>	<i>Estimated cost (£)</i>
<i>GP visit and usual treatment in primary care</i>	30 + 85
<i>Specialist visit(s)</i>	112 (per visit)
<i>Bed (per day)</i>	225
<i>Biopsy</i>	112
<i>Curettage and cautery</i>	137
<i>Mohs Surgery</i>	114
<i>Radiotherapy</i>	2260
<i>Radical lymph node dissection</i>	16,808

Table.2: non-exhaustive list of potential costs for skin cancer care to the NHS<sup>11,12,13</sup>

Late diagnoses merit more specialist care: e.g. a stage-IV melanoma might require an expensive radical lymph node dissection<sup>14</sup> or more follow-up appointments, which might have been avoided if the cancer was picked up earlier<sup>10,11</sup>. This is without considering the wider effects on the economy, such as the loss of working hours due to hospital admission(s) and/or loss of productive life due to a worsened prognosis<sup>15</sup>.

### How can we avoid delays?

Delays are a multifaceted problem and occasionally are unavoidable. One avenue for reducing delays is stopping the advent of SC at source, i.e., reducing UV exposure<sup>17,18</sup>; such

as by mass-media campaigns. Another method is increasing the supply of doctors, to meet the significant demand of patients needing SC care <sup>23,38</sup>.

#### Mass media campaigns:

TV programs were implemented in Australia (country with the highest rate of SC<sup>19</sup>) in the late 2000s and early 2010s <sup>20</sup>, which focused on advertising measures like regular sunscreen application and discouraging tanning bed use (interventions that significantly reduce cancer rates <sup>21,22</sup>). The effects of these campaigns were positive, translating into 13,174 less cases, and a net benefit of \$44.44 million <sup>20</sup>. In the UK, a similar campaign could be set up; although higher efficacy could be observed if newer modalities like social media are incorporated <sup>45</sup>. The importance of primary prevention cannot be overstated, as it can translate into a reduced caseload and fewer mortalities.

#### Increasing the supply of doctors:

In 2021, there were 659 consultant dermatologists in the UK; thus, there are 101,365 people per dermatologist <sup>23,42</sup>. According to the RCP, the target ratio for consultant dermatologist to the general population should be 1:62500 <sup>40</sup>. This highlights the shortfall of dermatologists within the NHS, which needs to be addressed to match demand. In the 2022 application cycle, dermatology had 41 slots and was again one of the most competitive specialities (ratio=5.46), which perpetuates the shortfall <sup>41</sup>. Research has suggested that the primary method to combat this is to increase the number of available training posts, which should result in greater numbers of dermatologists, and thus, less delays <sup>23</sup>.

### Meeting the psychosocial needs of patients:

There are several considerations in DS for surgeons like the margins for excision, location, etc <sup>24</sup>. However, the patient's perspective is equally vital because procedures with direct aesthetic consequences are notably associated with psychological disorders including body dysmorphic disorder, anxiety, and depression <sup>24, 25, 29</sup>. Thus, it is important to meet psychological needs due to the frequency of MH disorders in SC patients <sup>27</sup>, and in those undergoing cosmetic procedures <sup>28</sup>.

### How can these needs be met?

#### Minimising the aesthetic consequences of surgeries:

The nature of SC means that there is a significant visual component to the disease, like a facial lesion. This is compounded by surgeries that can result in scars <sup>30</sup>, which is a common concern for patients <sup>34, 35</sup>. These scars are associated with a reduction in body image, psychological distress, and social stigma <sup>35</sup>. Additionally, patients frequently underestimate the size of post-surgical scars <sup>36, 37</sup>. For surgeons, this illustrates the importance of having frank discussions with each patient prior to surgery about the potential characteristics of the scar(s), employing surgical techniques that achieve the best cosmetic outcome (while maximising clinical efficacy), and adequately explaining the best methods to maximise post-surgical wound healing.

What are some methods that can be used to improve mental health outcomes?

<u>Interventions</u>	<u>Notes</u>
<b>Ensuring that we meet the information needs of patients</b>	Skin cancer patients who are not well-informed about information like the risk of recurrence and further treatment, are associated with greater rates of psychological problems like anxiety, depression, sleeping difficulties, etc. <sup>43,44</sup>
<b>Behavioural therapies, e.g., cognitive behavioural therapy (CBT)</b>	Limited evidence showed that CBT was found to be a cost-effective intervention in melanoma patients who suffered from significant social distress <sup>46</sup> .
<b>Structured group programs</b>	A structured psychiatric intervention in a group setting involving teaching, enhancing problem-solving skills and stress-management techniques, resulted in better “active-behavioural coping” and lowering rates of depression, fatigue, and confusion <sup>48,49</sup> .

Table.3: Interventions that can be utilised to meet the psychosocial needs of patients.

Conclusion:

DS and SC research have several priorities, many require immediate attention. The effects of delays, especially the treatment of melanomas needs to be robustly addressed. Public health campaigns and increasing the number of skilled personnel are two of the many avenues through which this can be achieved. Furthermore, it is paramount to improve modalities of psychological support for SC patients, such as by being transparent, and making it easier to access pastoral care. Finally, research must be prioritised to develop newer modalities to address these issues as they are crucial in improving clinical outcomes.



## Bibliography:

1. Dermatological Surgery Information. asds.net. Accessed December 24, 2022. <https://www.asds.net/skin-experts/about-asds/dermatologic-surgery>
2. Brown A.C, et al. The top 10 research priorities for skin cancer surgery in the UK: results of a James Lind Alliance Priority Setting Partnership. *British Journal of Dermatology*. Published October 20,2022. Accessed December 21, 2022. <https://academic.oup.com/bjd/advance-article/doi/10.1093/bjd/ljac014/6763806#388577289>
3. Bowen GM, L. White George J, Gerwels JW. Mohs Micrographic Surgery. *American Family Physician*. 2005;72(5):845-848. <https://www.aafp.org/pubs/afp/issues/2005/0901/p845.html>
4. Ibrahim AE, Magdy M, Khalaf EM, Mostafa A, Arafa A. Teledermatology in the time of COVID-19. *International Journal of Clinical Practice*. 2021;75(12). doi:10.1111/ijcp.15000
5. Trepanowski N, Chang MS, Zhou G, et al. Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study. *Journal of the American Academy of Dermatology*. 2022;87(5):1217-1219. doi:10.1016/j.jaad.2022.06.031
6. US Deaths from Melanoma Drop Substantially - National Cancer Institute. www.cancer.gov. Published April 21, 2020. Accessed December 24, 2022. <https://www.cancer.gov/news-events/cancer-currents-blog/2020/metastatic-melanoma-deaths-drop>
7. Rachidi S, Deng Z, Sullivan DY, Lipson EJ. Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study. *Journal of the American Academy of Dermatology*. 2020;83(4):1012-1020. doi:10.1016/j.jaad.2020.05.088
8. Gajda M, Kaminska-Winciorek G. Do not let to be late: overview of reasons for melanoma delayed diagnosis. *Asian Pacific journal of cancer prevention: APJCP*. 2014;15(9):3873-3877. doi:10.7314/apjcp.2014.15.9.3873
9. Balch CM, Buzaid AC, Soong SJ, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. *Journal of Clinical Oncology*. 2001;19(16):3635-3648. doi:10.1200/jco.2001.19.16.3635
10. Renzi C, Mastroeni S, Mannooranparampil T, et al. Delay in Diagnosis and Treatment of Squamous Cell Carcinoma of the Skin. *Acta Dermato Venereologica*. 2010;90(6):595-601. doi:10.2340/00015555-0966
11. Vallejo-Torres L, Morris S, Kinge JM, Poirier V, Verne J. Measuring current and future cost of skin cancer in England. *Journal of Public Health*. 2014;36(1):140-148. doi:10.1093/pubmed/fdt032
12. NHS England. NHS England» Missed GP appointments costing NHS millions. England.nhs.uk. Published January 2, 2019. <https://www.england.nhs.uk/2019/01/missed-gp-appointments-costing-nhs-millions/>
13. Levell NJ, Wingfield CG, Garioch JJ. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. *British Journal of Dermatology*. 2011;164(6):1326-1328. doi:10.1111/j.1365-2133.2011.10275.x

14. Neuwirth MG, Bartlett EK, Karakousis GC. Lymph node dissection for melanoma: where do we stand? *Melanoma Management*. 2017;4(1):49-59. doi:10.2217/mmt-2016-0023
15. Guy GP, Ekwueme DU. Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer. *PharmacoEconomics*. 2011;29(10):863-874. doi:10.2165/11589300-000000000-00000
16. Ravitskiy L, Brodland DG, Zitelli JA. Cost Analysis: Mohs Micrographic Surgery. *Dermatologic Surgery*. 2012;38(4):585-594. doi:10.1111/j.1524-4725.2012.02341.x
17. Skin cancer (non-melanoma) - Causes. NHS. Published October 3, 2018. <https://www.nhs.uk/conditions/non-melanoma-skin-cancer/causes/>
18. NHS Choices. Causes - Skin cancer (melanoma). NHS. Published 2019. <https://www.nhs.uk/conditions/melanoma-skin-cancer/causes/>
19. *Global Coalition | Euromelanoma | 2020 Melanoma Skin Cancer Report 2 Euromelanoma*. <https://www.melanomauk.org.uk/Handlers/Download.ashx?IDMF=91e70826-91d1-4b5e-9b0c-3dd3da10686d>
20. Doran CM, Ling R, Byrnes J, et al. Benefit Cost Analysis of Three Skin Cancer Public Education Mass-Media Campaigns Implemented in New South Wales, Australia. van Steensel MAM, ed. *PLOS ONE*. 2016;11(1):e0147665. doi:10.1371/journal.pone.0147665
21. Gasparro FP, Mitchnick M, Nash JF. A review of sunscreen safety and efficacy. *Photochemistry and Photobiology*. 1998;68(3):243-256. Published June 23, 2021. <https://pubmed.ncbi.nlm.nih.gov/9747581/>
22. Zhang M, Qureshi AA, Geller AC, Frazier L, Hunter DJ, Han J. Use of Tanning Beds and Incidence of Skin Cancer. *Journal of Clinical Oncology*. 2012;30(14):1588-1593. doi:10.1200/jco.2011.39.3652
23. *GIRFT Recommendations Address Dermatology Workforce Shortages and Call for Wider Use of Technology*. <https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/11/Dermatology-overview.pdf>
24. Ishizuki S, Nakamura Y. Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer. *Cancers*. 2022;14(15):3835. doi:10.3390/cancers14153835
25. Sarwer DB, Wadden TA, Pertschuk MJ, Whitaker LA. THE PSYCHOLOGY OF COSMETIC SURGERY: A REVIEW AND RECONCEPTUALIZATION. *Clinical Psychology Review*. 1998;18(1):1-22. doi:10.1016/s0272-7358(97)00047-0
26. Risks and complications of skin surgery | DermNet NZ. [dermnetnz.org. https://dermnetnz.org/topics/risks-and-complications-of-skin-surgery](https://dermnetnz.org/topics/risks-and-complications-of-skin-surgery)
27. Burdon-Jones D, Thomas P, Baker R. Quality of life issues in nonmetastatic skin cancer. *British Journal of Dermatology*. 2009;162(1):147-151. doi:10.1111/j.1365-2133.2009.09469.
28. Sansone RA, Sansone LA. Cosmetic surgery and psychological issues. *Psychiatry (Edgmont (Pa : Township))*. 2007;4(12):65-68. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861519/>
29. The role of surgery in dermatology | DermNet. [dermnetnz.org. https://dermnetnz.org/topics/the-role-of-surgery-in-dermatology](https://dermnetnz.org/topics/the-role-of-surgery-in-dermatology)

30. After surgery | Skin cancer | Cancer Research UK. [www.cancerresearchuk.org](http://www.cancerresearchuk.org). Accessed December 29, 2022. <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/surgery/surgery-for-larger-skin-cancers/after-surgery>
31. Alam M, Goldberg LH, Silapunt S, et al. Delayed treatment and continued growth of nonmelanoma skin cancer. *Journal of the American Academy of Dermatology*. 2011;64(5):839-848. doi:10.1016/j.jaad.2010.06.028
32. Rashid S, Tsao H. Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services. *Dermatologic Clinics*. Published online May 2021. doi:10.1016/j.det.2021.05.015
33. Cancer Research UK. Survival | Melanoma | Cancer Research UK. [Cancerresearchuk.org](http://www.cancerresearchuk.org). Published 2016. <https://www.cancerresearchuk.org/about-cancer/melanoma/survival>
34. Xavier MHSB, Drummond-Lage AP, Baeta C, Rocha L, Almeida AM, Wainstein AJA. Delay in cutaneous melanoma diagnosis. *Medicine*. 2016;95(31):e4396. doi:10.1097/md.0000000000004396
35. Ngaage M, Agius M. The Psychology of Scars: A Mini-Review. *Psychiatria Danubina*. 2018;30(Suppl 7):633-638. <https://pubmed.ncbi.nlm.nih.gov/30439862/>
36. Fix WC, Miller CJ, Etzkorn JR, Shin TM, Howe N, Sobanko JF. Comparison of Accuracy of Patient and Physician Scar Length Estimates Before Mohs Micrographic Surgery for Facial Skin Cancers. *JAMA Network Open*. 2020;3(3):e200725. doi:10.1001/jamanetworkopen.2020.0725
37. Most patients underestimate likely scar size before Moh's surgery. *Reuters*. <https://www.reuters.com/article/us-health-cancer-skin-idUSKBN20Z3PJ>. Published March 12, 2020. Accessed January 2, 2023.
38. NHS England» The two-week wait skin cancer pathway: innovative approaches to support early diagnosis of skin cancer as part of the NHS COVID-19 recovery plan. [www.england.nhs.uk](http://www.england.nhs.uk). <https://www.england.nhs.uk/publication/the-two-week-wait-skin-cancer-pathway-innovative-approaches-to-support-early-diagnosis-of-skin-cancer-as-part-of-the-nhs-covid-19-recovery-plan/>
39. 2019 Audit of UK Dermatology Coverage. [www.appgs.co.uk](http://www.appgs.co.uk). Accessed January 3, 2023. <https://www.appgs.co.uk/publication/2019-audit-of-uk-dermatology-coverage/>
40. *Consultant Physicians Working with Patients the Duties, Responsibilities and Practice of Physicians in Medicine*. <https://www.rcplondon.ac.uk/file/1578/download>
41. 2022 Competition ratios | Health Education England. Health Education England | Medical Education Hub. <https://medical.hee.nhs.uk/medical-training-recruitment/medical-specialty-training/competition-ratios/2022-competition-ratios>
42. Office for National Statistics. Overview of the UK population - Office for National Statistics. [www.ons.gov.uk](http://www.ons.gov.uk). Published January 14, 2021. <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/january2021>
43. Kasparian NA. Psychological stress and melanoma: Are we meeting our patients' psychological needs? *Clinics in Dermatology*. 2013;31(1):41-46. doi:10.1016/j.clindermatol.2011.11.005
44. Bonevski B, Sanson-Fisher R, Hersey P, Paul C, Foot G. Assessing the Perceived Needs of Patients Attending an Outpatient Melanoma Clinic. *Journal of Psychosocial Oncology*. 1999;17(3-4):101-118. doi:10.1300/j077v17n03\_06

45. Taber JM, Dickerman BA, Okhovat JP, et al. Skin cancer interventions across the cancer control continuum: Review of technology, environment, and theory. *Preventive Medicine*. 2018;111:451-458. doi:10.1016/j.ypmed.2017.12.019
46. Bares CB, Trask PC, Schwartz SM. *Journal of Clinical Psychology in Medical Settings*. 2002;9(3):193-200. doi:10.1023/a:1016095126552
47. 9 in 10 dermatologists agree not enough importance is placed on the psychological effects of skin conditions. British Skin Foundation.  
<https://www.britishskinfoundation.org.uk/news/nine-in-ten-dermatologists-agree-that-not-enough-importance-is-placed-on-the-psychological-effects-resulting-from-skin-conditions>
48. Fawzy FI, et al. A Structured Psychiatric Intervention for Cancer Patients. *Archives of General Psychiatry*. 1990;47(8):720. doi:10.1001/archpsyc.1990.01810200028004
49. Grassi L, Spiegel D, Riba M. Advancing psychosocial care in cancer patients. *F1000Research*. 2017;6(1):2083. doi:10.12688/f1000research.11902.1